Can a new drug tame advanced solid tumors?

NCT ID NCT02561234

Completed Disease control Sponsor: Immedica Pharma AB Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's side effects. Participants receive the drug through an IV, and the study will monitor their health closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AEB1102 (Co-Arg1-PEG), an experimental drug given by IV infusion
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early, first-in-human trial focused on safety and dosing, so it may not lead to an effective treatment. There are also potential side effects from the drug, which are being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma neoplasm small cell lung carcinoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCERS

Contacts and locations

Locations

Columbia University

New York, New York, 10032, United States
Dana Farber

Boston, Massachusetts, 02114, United States
Massachusetts General

Boston, Massachusetts, 02114, United States
Pinnacle Research

Phoenix, Arizona, 85258, United States
Providence Cancer Center

Portland, Oregon, 97213, United States
Research Center: Mid Florida Hematology/Oncology Centers

Orange City, Florida, 32763, United States
UCLA

Los Angeles, California, 90024, United States
UTSW

Dallas, Texas, 75390-8852, United States
University of Colorado

Aurora, Colorado, 80045, United States
University of Pittsburgh

Pittsburgh, Pennsylvania, 15232, United States
Washington University

St Louis, Missouri, 93110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.